|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Ranbaxy_Laboratories
|
|
gptkbp:acquisitionYear
|
2014
|
|
gptkbp:CEO
|
gptkb:Dilip_Shanghvi
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focusArea
|
Acute therapies
Chronic therapies
Generics
OTC products
Specialty medicines
|
|
gptkbp:foundedBy
|
gptkb:Dilip_Shanghvi
|
|
gptkbp:foundedYear
|
1983
|
|
gptkbp:fullName
|
gptkb:Sun_Pharmaceutical_Industries_Limited
|
|
gptkbp:hasResearchCenter
|
gptkb:Canada
gptkb:Hungary
gptkb:India
gptkb:Israel
gptkb:United_States
|
|
gptkbp:headquartersLocation
|
gptkb:Mumbai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sun Pharma
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Dilip_Shanghvi
gptkb:Israel_Makov
|
|
gptkbp:listedOn
|
gptkb:Bombay_Stock_Exchange
gptkb:National_Stock_Exchange_of_India
|
|
gptkbp:manufacturingFacilities
|
gptkb:Africa
gptkb:Asia
gptkb:Australia
gptkb:Europe
gptkb:India
gptkb:United_States
|
|
gptkbp:market
|
over 100 countries
|
|
gptkbp:netIncomeFY2023
|
INR 85.8 billion
|
|
gptkbp:notableProduct
|
gptkb:Absorica
gptkb:BromSite
gptkb:Cequa
gptkb:Ilumya
gptkb:Odomzo
gptkb:Yonsa
|
|
gptkbp:numberOfEmployees
|
over 37,000
|
|
gptkbp:products
|
Active pharmaceutical ingredients
Generic drugs
Specialty medicines
|
|
gptkbp:rank
|
Among top 10 generic pharmaceutical companies worldwide
Largest pharmaceutical company in India by market capitalization
|
|
gptkbp:revenueFY2023
|
INR 432.6 billion
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:stockSymbol
|
gptkb:SUNPHARMA
|
|
gptkbp:subsidiary
|
gptkb:Sun_Pharma_Advanced_Research_Company
gptkb:Taro_Pharmaceutical_Industries
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.sunpharma.com/
|
|
gptkbp:bfsParent
|
gptkb:Reliance_Industries
gptkb:NOVN
|
|
gptkbp:bfsLayer
|
5
|